Recent Updates
Recently added Catalysts
BIOA Negative Sentiment Score: 25/100

BioAge Labs, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights – BIOA

Key Takeaway: Levi & Korsinsky, LLP has initiated a class action lawsuit against BioAge Labs, Inc. regarding alleged securities fraud affecting investors of the company. The lawsuit pertains to shareholders who purchased stock related to BioAge's IPO on September 26, 2024. Negative news about the discontinuation of the STRIDES Phase 2 trial for azelaprag due to safety concerns resulted in a steep decline in the company's stock price from $20.09 to $4.65 within a day. Investors affected by this are encouraged to contact the firm before the March 10, 2025 deadline to discuss recovery options.

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action lawsuit filed against BioAge Labs due to alleged securities fraud.
  • Stock price dropped significantly following the announcement of trial discontinuation for azelaprag.
  • Concerns raised about safety of azelaprag, impacting investor confidence.

Full Press Release Details

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ: BIOA) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioAge investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to BioAge’s registration statement for the initial public offering held on or about September 26, 2024. Follow the link below to get more information and be contacted by a member of our team:
BIOA investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: According to the complaint, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 trial for azelaprag, its lead product candidate, citing safety concerns over elevated liver transaminase levels in participants. This came as a surprise because, at the time of its IPO less than three months earlier, BioAge highlighted azelaprag's potential in patients undergoing obesity therapy with incretin drugs. Following this news, BioAge’s stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024.
WHAT'S NEXT? If you suffered a loss in BioAge during the relevant time frame, you have until March 10, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 17th Floor

Tags

Frequently Asked Questions

What lawsuit involves BioAge Labs, Inc.?

A class action securities lawsuit has been filed against BioAge Labs for alleged fraud.

What is the class definition for the lawsuit?

The lawsuit aims to recover losses for all BioAge investors affected by securities fraud.

When is the deadline to join the lawsuit?

Investors have until March 10, 2025, to request lead plaintiff status.

Will it cost me to participate in the lawsuit?

Participation in the class action may involve no out-of-pocket costs for members.

How did BioAge's stock price change after December 6, 2024?

The stock price fell from $20.09 to $4.65 following negative trial news.

Last updated: Mar 4, 2025